AR080564A1 - Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3) - Google Patents

Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3)

Info

Publication number
AR080564A1
AR080564A1 ARP100104211A AR080564A1 AR 080564 A1 AR080564 A1 AR 080564A1 AR P100104211 A ARP100104211 A AR P100104211A AR 080564 A1 AR080564 A1 AR 080564A1
Authority
AR
Argentina
Prior art keywords
agent
prevention
receiver
treatment
methods
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Robert Radinsky
Thore Hettmann
Daniel J Freeman
Original Assignee
U3 Pharma Gmbh
Amgen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U3 Pharma Gmbh, Amgen filed Critical U3 Pharma Gmbh
Publication of AR080564A1 publication Critical patent/AR080564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP100104211 2009-11-13 2010-11-15 Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3) AR080564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26114909P 2009-11-13 2009-11-13

Publications (1)

Publication Number Publication Date
AR080564A1 true AR080564A1 (es) 2012-04-18

Family

ID=43618172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104211 AR080564A1 (es) 2009-11-13 2010-11-15 Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3)

Country Status (26)

Country Link
US (4) US9101760B2 (OSRAM)
EP (5) EP2719708B1 (OSRAM)
JP (5) JP5931736B2 (OSRAM)
KR (1) KR101806323B1 (OSRAM)
CN (2) CN105999263B (OSRAM)
AR (1) AR080564A1 (OSRAM)
AU (1) AU2010319483B2 (OSRAM)
BR (1) BR112012012160B1 (OSRAM)
CA (1) CA2780935C (OSRAM)
CY (2) CY1119751T1 (OSRAM)
DK (2) DK3351558T3 (OSRAM)
ES (3) ES2655737T3 (OSRAM)
HK (1) HK1207651A1 (OSRAM)
HR (2) HRP20180104T1 (OSRAM)
HU (2) HUE035605T2 (OSRAM)
LT (2) LT2719708T (OSRAM)
MX (3) MX358013B (OSRAM)
NO (1) NO2719708T3 (OSRAM)
PL (2) PL3351558T3 (OSRAM)
PT (2) PT3351558T (OSRAM)
RS (2) RS60390B1 (OSRAM)
SI (2) SI3351558T1 (OSRAM)
SM (2) SMT202000267T1 (OSRAM)
TW (1) TWI630916B (OSRAM)
UY (1) UY33034A (OSRAM)
WO (1) WO2011060206A2 (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CN102356092B (zh) * 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
AU2015201262B2 (en) * 2009-11-13 2017-04-27 Amgen Inc. Material and methods for treating or preventing her-3 associated diseases
NO2719708T3 (OSRAM) * 2009-11-13 2018-03-24
DK2516469T3 (en) 2009-12-22 2016-05-02 Roche Glycart Ag ANTI-HER3 antibodies and uses thereof
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
JP6271432B2 (ja) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥｒｂＢ３抗体およびその使用
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
AU2012349735B2 (en) * 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140099315A (ko) * 2011-12-05 2014-08-11 노파르티스 아게 Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
JP2015509492A (ja) * 2012-02-22 2015-03-30 ユー３・ファーマ・ゲーエムベーハー Ｈｂ−ｅｇｆ結合タンパク質およびｅｇｆｒ阻害剤の組合せ
US10357566B2 (en) * 2012-02-23 2019-07-23 Daiichi Sankyo Europe Gmbh HER3 inhibitor for modulating radiosensitivity
WO2013164689A2 (en) * 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
EP2885321A4 (en) * 2012-08-14 2016-03-30 Angiochem Inc CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
CN105026432A (zh) * 2012-11-12 2015-11-04 安吉奥开米公司 抑肽酶衍生的多肽-抗体缀合物
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
RU2711640C2 (ru) * 2014-04-10 2020-01-17 Дайити Санкио Компани, Лимитед Конъюгат анти-her3 антитело-лекарственное средство
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
CA2959775A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CN104861068B (zh) * 2015-01-23 2020-11-17 中国人民解放军军事科学院军事医学研究院 一种全人源抗her3抗体及其治疗相关疾病的用途
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN107922477B (zh) 2015-06-29 2022-11-01 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
WO2017102789A1 (en) * 2015-12-17 2017-06-22 F. Hoffmann-La Roche Ag Combination therapy of anti-her3 antibodies and anti-her2 antibodies
EP3512886B1 (en) * 2016-09-15 2025-06-11 Universität Stuttgart Antigen binding protein against her3
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
KR20240074000A (ko) * 2017-02-28 2024-05-27 다이이찌 산쿄 가부시키가이샤 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
AU2018258663B2 (en) * 2017-04-28 2022-08-04 Seagen Inc. Treatment of HER2 positive cancers
TW202530219A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
US20210246223A1 (en) * 2018-06-22 2021-08-12 Crd Pharmaceuticals Inc ANTI-HER3 Antibody and uses thereof
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化
KR20240153994A (ko) * 2022-03-03 2024-10-24 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Her3 결합 단백질 및 그의 용도
CA3256212A1 (en) * 2022-04-29 2023-11-02 Sichuan Kelun Biotech Biopharmaceutical Co Ltd ANTIBODY-DRUG CONJUGATES, PREPARATION PROCESSES AND ASSOCIATED USES

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4471052A (en) 1982-01-18 1984-09-11 Adria Laboratories, Inc. Biosynthesis of simplified anthracyclines
JPS58166633A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
JPS58166634A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
JPS62170639A (ja) 1986-01-22 1987-07-27 株式会社システムメンテナンス 防蟻板の取付け工法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US4939168A (en) 1989-08-11 1990-07-03 Harbor Branch Oceanographics Institution, Inc. Discodermolide compounds, compositions containing same and methods of preparation and use
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング　ビーブイ 哺乳動物細胞における相同性組換え
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH07508410A (ja) 1992-06-18 1995-09-21 ジェンファーム　インターナショナル　インコーポレイテッド 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995014776A1 (en) * 1993-11-23 1995-06-01 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
FR2718135B1 (fr) 1994-04-05 1996-04-26 Rhone Poulenc Rorer Sa Procédé de préparation d'hydroxy-7 taxanes.
FR2721928A1 (fr) 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
TW321649B (OSRAM) 1994-11-12 1997-12-01 Zeneca Ltd
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
CA2230759C (en) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Chimeric animal and method for producing the same
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PT896586E (pt) 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
US6114595A (en) * 1996-04-11 2000-09-05 The Procter & Gamble Company Stretchable, extensible composite topsheet for absorbent articles
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU5596998A (en) 1996-12-11 1998-07-03 New York University Medical Center Pyk2 related products and methods
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
WO2000040971A1 (en) 1998-12-31 2000-07-13 Sugen, Inc. Pyk2 (raftk) and inflammation
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2111870A1 (en) 1999-08-27 2009-10-28 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
FR2817258B1 (fr) * 2000-11-27 2003-01-10 Atofina Procede de sulfochloration photochimique d'alcanes gazeux
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4424987B2 (ja) 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
US7435871B2 (en) * 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
US7754433B2 (en) 2001-12-03 2010-07-13 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
CN1219882C (zh) 2002-03-18 2005-09-21 上海泽生科技开发有限公司 以erbb－3为基础的用于肿瘤治疗的方法和组合物
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
EP1540347B1 (en) 2002-07-25 2009-09-09 Aclara BioSciences, Inc. Detecting receptor oligomerization
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2004087887A2 (en) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
JP2005024385A (ja) 2003-07-02 2005-01-27 Matsushita Electric Ind Co Ltd 感圧センサ
MX2007008768A (es) * 2005-01-21 2007-10-19 Genentech Inc Dosificacion fija de anticuerpos her.
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101351563A (zh) * 2005-10-05 2009-01-21 阿斯利康(英国)有限公司 用于预测或监测病人对于ErbB受体药物的响应的方法
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
HRP20131113T1 (hr) * 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
EP2467164A2 (en) * 2009-08-21 2012-06-27 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
NO2719708T3 (OSRAM) * 2009-11-13 2018-03-24
JP2013540694A (ja) * 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
US12365733B2 (en) 2017-12-29 2025-07-22 Cellectis Method for improving production of car T cells

Also Published As

Publication number Publication date
JP2022000445A (ja) 2022-01-04
PT2719708T (pt) 2018-01-16
EP2719708A2 (en) 2014-04-16
RS60390B1 (sr) 2020-07-31
EP2719708B1 (en) 2017-10-25
CN102812045A (zh) 2012-12-05
SMT202000267T1 (it) 2020-07-08
BR112012012160B1 (pt) 2022-04-26
EP3670539A1 (en) 2020-06-24
CN102812045B (zh) 2018-04-13
CN105999263A (zh) 2016-10-12
KR20120114262A (ko) 2012-10-16
JP7317650B2 (ja) 2023-07-31
EP2499162A2 (en) 2012-09-19
EP2896632A2 (en) 2015-07-22
EP3351558A2 (en) 2018-07-25
AU2010319483B2 (en) 2015-03-12
US20180134805A1 (en) 2018-05-17
EP3351558A3 (en) 2018-08-29
US20110229406A1 (en) 2011-09-22
SI3351558T1 (sl) 2020-07-31
HUE035605T2 (en) 2018-05-28
JP2013510868A (ja) 2013-03-28
LT2719708T (lt) 2018-02-12
EP2896632A3 (en) 2015-08-19
US20160222126A1 (en) 2016-08-04
JP2018076300A (ja) 2018-05-17
US20140017166A1 (en) 2014-01-16
CY1119751T1 (el) 2018-06-27
JP5931736B2 (ja) 2016-06-08
CA2780935A1 (en) 2011-05-19
WO2011060206A3 (en) 2011-09-09
WO2011060206A2 (en) 2011-05-19
JP2016128430A (ja) 2016-07-14
MX358013B (es) 2018-08-01
NO2719708T3 (OSRAM) 2018-03-24
LT3351558T (lt) 2020-06-10
MX357972B (es) 2018-08-01
UY33034A (es) 2011-05-31
SI2719708T1 (en) 2018-03-30
BR112012012160A2 (pt) 2017-01-10
DK3351558T3 (da) 2020-06-02
ES2655737T3 (es) 2018-02-21
US12139549B2 (en) 2024-11-12
US9101760B2 (en) 2015-08-11
HK1207651A1 (en) 2016-02-05
CN105999263B (zh) 2021-06-29
JP6235620B2 (ja) 2017-11-22
PL3351558T3 (pl) 2020-08-24
RS56741B1 (sr) 2018-03-30
CY1123030T1 (el) 2021-10-29
PT3351558T (pt) 2020-04-09
AU2010319483A1 (en) 2012-05-31
HUE049880T2 (hu) 2020-10-28
JP2020011980A (ja) 2020-01-23
EP2719708A3 (en) 2014-09-03
ES2781299T3 (es) 2020-09-01
US9988462B2 (en) 2018-06-05
TW201129378A (en) 2011-09-01
EP2896632B1 (en) 2017-10-25
HRP20200921T1 (hr) 2020-09-18
MX349513B (es) 2017-08-02
SMT201800167T1 (it) 2018-05-02
MX2012005589A (es) 2012-11-30
US9803025B2 (en) 2017-10-31
KR101806323B1 (ko) 2017-12-07
CA2780935C (en) 2022-05-24
DK2719708T3 (da) 2018-01-29
HRP20180104T1 (hr) 2018-03-09
TWI630916B (zh) 2018-08-01
PL2719708T3 (pl) 2018-04-30
EP3351558B1 (en) 2020-03-11
ES2647466T3 (es) 2017-12-21

Similar Documents

Publication Publication Date Title
AR080564A1 (es) Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3)
AR085955A1 (es) Proteinas de union al antigeno
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
BR112019012040A2 (pt) anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73.
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AR076607A1 (es) Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo
AR062840A1 (es) Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)
GT200900248A (es) "proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpo, que unen especificamente a cd154 y sus usos"
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
RU2014111472A (ru) Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
ZA202302392B (en) Antibodies against ilt2 and use thereof
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
RU2016148682A (ru) Антитела против рецептора-3 к эпидермальному ростовому фактору человека (her3), связывающиеся с бета-шпилькой her3
WO2017100663A8 (en) Improved methods for treating her2-positive breast cancer
US20190016798A1 (en) Anti-neurotensin antibodies and uses thereof
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
AR074398A1 (es) Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa
Kedzior et al. Challenges in comparing the acute cognitive outcomes of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) vs. electroconvulsive therapy (ECT) in major depression: a systematic review
HK1220141A1 (zh) 二价疫苗组合物以及其用於治疗肿瘤的用途
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
CN109640979A (zh) 用于减少干扰素水平的化合物
BR112021021626A2 (pt) Proteína selecionada a partir do grupo que consiste em chrdll, fam3c, fam3b e fragmentos da mesma ou um polinucleotídeo que codifica a mesma, proteína ou polinucleotídeo para uso, vetor para uso no tratamento ou redução do risco de doença cardíaca, e, composição farmacêutica
BR112021019478A2 (pt) Primeira, segunda e terceira proteínas de fusão compreendendo anticorpos anti-mesotelina, anti-cd3 e anti-egfr, anticorpos biespecífico e triespecífico, composição farmacêutica que compreende os mesmos e usos das ditas proteínas e anticorpos, bem como da dita composição farmacêutica para tratar câncer

Legal Events

Date Code Title Description
FB Suspension of granting procedure